|
Jun 24
|
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
|
|
May 20
|
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
|
|
May 9
|
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 9
|
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
|
|
Apr 4
|
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
|
|
Mar 25
|
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Jan 29
|
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Jan 25
|
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Jan 9
|
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
|
|
Jan 9
|
eFFECTOR Therapeutics Announces Reverse Stock Split
|
|
Dec 8
|
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
|
|
Nov 28
|
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
|
|
Nov 6
|
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
|
|
Aug 8
|
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|